Cardiol Therapeutics (CRDL) Has a New Rating from Brookline Capital Markets
Cardiol Therapeutics received a Buy rating and a $6.00 price target from Brookline Capital Markets analyst Tyler Bussian yesterday. The company’s shares closed yesterday at $1.08.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Bussian is a 4-star analyst with an average return of 56.1% and a 33.33% success rate.
Currently, the analyst consensus on Cardiol Therapeutics is a Strong Buy with an average price target of $9.50, a 779.63% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.
The company has a one-year high of $2.44 and a one-year low of $0.77. Currently, Cardiol Therapeutics has an average volume of 757.8K.
Read More on CRDL:
Disclaimer & DisclosureReport an Issue
- Cardiol Therapeutics: Promising Developments in Cardiac Disease Treatment with CardiolRx
- Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses
- Cardiol Therapeutics to Present at Canaccord Genuity Conference
- Roth bullish on Cardiol, says trial results enough to attract larger partner
- Optimistic Buy Rating for Cardiol Therapeutics Amid Promising Clinical Trial Results and Strategic Advancements
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.